Physiologix™ Serum Replacement: The Proven Supplement For CAR-T Solid Tumor Cytotoxicity

By Asma Ayari, Ph.D., Director of Research and Development, Nucleus Biologics

Solid tumors pose significant challenges in oncology due to the suppressive tumor microenvironment, which hinders immune cell function and infiltration. For researchers developing novel cell therapies, optimizing cell culture conditions is essential to achieve robust cell expansion and maximum tumor-killing potency. Studies have reinforced that the choice of media supplement significantly impacts cell performance, phenotype, and cytotoxicity.

A xeno-free, GMP-ready serum replacement has been shown to improve the therapeutic potential of CAR-T cells in challenging solid tumor models. Data published in collaboration with the University of Pennsylvania demonstrated that using this optimized supplement enhanced the in vivo efficacy and anti-tumor response of CAR-T cells against a solid neuroblastoma model compared to cells grown in human serum. Discover how a consistent, high-performing serum replacement can help overcome solid tumor barriers and accelerate your research towards clinical success.